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Abstract  36 
Background: A recent randomized trial (the LEAP study) provided evidence that earlier dietary 37 
peanut introduction reduces peanut allergy prevalence in high-risk infants. However, questions remain 38 
as to how to identify and target the “at risk” population to facilitate timely introduction of peanut 39 
Objective: To use population-based infant peanut allergy data to understand feasibility and 40 
implications of implementing the LEAP trial intervention  41 
Methods: Using the HealthNuts cohort (n=5,300) of 1-year-old infants, we explored the impact of 42 
using various criteria to identify infants at high risk of developing peanut allergy, and the implications 43 
of skin prick test (SPT) screening prior to peanut introduction 44 
Results: Screening all infants with early onset eczema and/or egg allergy could require testing 16% of 45 
the population and would still miss 23% of peanut allergy cases. 29% of screened infants would 46 
require clinical follow up due to being SPT positive. Around 11% of high-risk infants were excluded 47 
from LEAP due to SPT wheal size >4mm to peanut at baseline; data from HealthNuts suggest 80% of 48 
these would be peanut allergic on food challenge. There were no life-threatening events among either 49 
low- or high-risk infants whose parents chose to introduce peanut at home in the first year of life, or in 50 
150 peanut-allergic infants during hospital based challenges.  51 
Conclusions: Based on this large epidemiological study, a population program aiming to identify and 52 
screen all infants at risk of peanut allergy would pose major cost and logistic challenges that need to 53 
be carefully considered. Further research might be required to provide data for low-risk infants.  54 
Clinical implications:  55 
The LEAP findings are of major significance for the prevention of peanut allergy. The public health 56 
and workforce implications of the LEAP study will need to be carefully considered if implemented at 57 
the population level.  58 
Key words:  59 
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Peanut allergy; infant feeding; guidelines; skin prick test; specific IgE; prevention  60 
Abbreviations:  61 
SPT: Skin prick test 62 
OFC: Oral food challenge 63 
sIgE: Specific IgE  64 
LEAP: Learning Early About Peanut Allergy, a randomized trial of peanut consumption compared 65 
with peanut avoidance in infants with severe eczema and/or egg allergy for the prevention of peanut 66 
allergy 67 
 68 
Capsule summary: Using data from a large epidemiological study, we explore potential criteria for 69 
identifying infants at high risk of developing peanut allergy and the implications of skin prick test 70 
screening prior to peanut introduction at the population level. 71 
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Introduction  73 
The recent publication of the LEAP (Learning Early About Peanut Allergy) randomized trial provided 74 
direct evidence in high-risk infants (defined as those with severe eczema and/or egg allergy) that 75 
delayed introduction of dietary peanut increases the risk of peanut allergy.1 This is the first 76 
randomized trial to describe a prevention strategy for peanut allergy. With reports from the UK, US 77 
and Australia that the prevalence of peanut allergy is around 1-3%,2-4 and evidence that peanut 78 
introduction is delayed in a high proportion of children in these countries,5,6 a shift towards earlier 79 
introduction of peanut in infants is likely to significantly reduce the burden of peanut allergy. How to 80 
achieve this safely and in a cost-effective manner is currently the subject of intense debate. 81 
An editorial accompanying publication of the LEAP study suggested “any infant between 4 months 82 
and 8 months of age believed to be at risk for peanut allergy should undergo skin-prick testing (SPT) 83 
for peanut. If the test results are negative, the child should be started on a [peanut containing diet]… 84 
and if the results are positive but show mild sensitivity (i.e., the wheal measures 4 mm or less), the 85 
child should undergo a food challenge” (Gruchalla and Sampson).7 However, no published data are 86 
currently available to determine what proportion of the population fall in to the category of “high 87 
risk” (thus how many infants would need SPT), what proportion of the high-risk group will develop 88 
peanut allergy, and what proportion of all peanut allergy cases occur in high-risk compared with low-89 
risk infants. An additional question that arises from the LEAP study is what proportion of infants with 90 
a greater than 4mm peanut SPT wheal size (the cut-off used in LEAP to define likely peanut allergy) 91 
are truly peanut allergic, and thus whether this group should potentially undergo formal oral food 92 
challenge (OFC) prior to recommending peanut avoidance.  93 
Interim guidelines have also been released as a result of the LEAP findings, based on consensus 94 
among multiple allergy organizations worldwide. These recommend introduction of peanut between 95 
4-11 months of age, in infants with severe eczema or egg allergy, in countries where peanut allergy is 96 
prevalent. The guidelines also suggest that infants with severe eczema or egg allergy in the first 4-6 97 
months of life might benefit from evaluation by an allergist or physician trained in management of 98 
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allergic disease – including potentially SPT and in-office observed peanut ingestion.8 Data 99 
characterizing SPT and specific IgE (sIgE) values to peanut in the high-risk population of infants, and 100 
their relationship to peanut allergy, may help to define the impact on the allergy workforce if this 101 
advice is followed, and inform strategies for determining which infants require supervised peanut 102 
challenges. Finally, data on the likelihood of reactions, particularly severe reactions, in young infants 103 
exposed to peanut in early life is also likely to be useful in addressing these questions.  104 
In a recent companion study to the LEAP trial, the EAT (Enquiring About Tolerance) randomized 105 
trial compared early introduction (from 3 months of age) of allergenic foods including peanut with 106 
standard introduction (from 6 months of age) in infants recruited from the general population.9 The 107 
EAT trial included infants with and without existing allergic disease (eczema) and infants in the 108 
control (standard introduction) arm were only required to avoid allergenic foods until 6 months of 109 
age. By comparison in the LEAP trial the control arm avoided peanut until age 5 years. Compliance 110 
with the intervention in the EAT trial was also lower than in the LEAP trial. There was no evidence of 111 
a statistically significant difference in food allergy prevalence at age 1-3 years between the early and 112 
standard introduction arms in the primary intention-to-treat analysis. The failure to demonstrate 113 
efficacy of early introduction of allergenic foods in EAT could potentially be due to low compliance 114 
with the early introduction intervention (consumption of sufficient doses of the allergenic foods), or 115 
because the age at allergen introduction in the intervention (median reported age approximately 5 116 
months) and control arms (introduced from 6 months, actual age not reported) might not have been 117 
different enough to have a biological impact.   118 
We aimed to use data from the HealthNuts study, a population-based cohort of 5,300 infants in 119 
Australia, to understand the implications and generalisability of the LEAP findings regarding 120 
introduction of peanut at the population level. The HealthNuts population provides an ideal 121 
opportunity to examine these issues, since all infants underwent SPT screening to peanut using the 122 
same technique, device and extract used in the LEAP study, and infants with any detectable wheal 123 
underwent an OFC to peanut, irrespective of SPT wheal size or history of previous ingestion or 124 
reaction, unless a clear reaction had occurred in the past month.   125 
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Methods 126 
HealthNuts study population 127 
HealthNuts is a large-scale, population-based cohort study undertaken to assess the prevalence and 128 
risk factors for allergic disease in early childhood.10,11 Briefly, by using a predetermined population-129 
based sampling frame drawn from local government–led immunization clinics in Melbourne, 130 
Australia (population four million), infants were recruited while attending one-year-old immunization. 131 
All infants aged between 11 and 15 months (inclusive) were eligible for recruitment (74% response 132 
rate). Parents completed a questionnaire prior to SPT that included questions about the child’s history 133 
of peanut consumption and food reactions, and history of eczema (including whether diagnosed, age 134 
at diagnosis and history of medication use).  135 
Infants were skin prick tested to four foods including peanut and hen’s egg (ALK-Abelló, Madrid, 136 
Spain), with a positive control (histamine 10 mg/mL), and a negative control (saline) using single-tine 137 
lancets on the infant’s back. All participants with a detectable wheal to one or more foods were 138 
invited to a hospital–based clinic where staff administered repeat SPT and diagnostic OFCs, blinded 139 
to the infant’s SPT wheal size and history of ingestion. A positive challenge was defined based on 140 
pre-specified objective criteria12: hives (3 or more hives lasting at least 5 minutes); vomiting; 141 
angioedema or anaphylaxis (evidence of circulatory or respiratory involvement), occurring within 2 142 
hours of ingestion of the food. We chose any detectable wheal size as our entry criterion to assess the 143 
food allergy status of participants to minimize the chances of missing cases of food allergy. A random 144 
sample of infants with negative SPT results was also invited to undergo a food challenge (negative 145 
controls for the clinic study). SPT was performed with peanut extracts purchased from the same 146 
company employed in the LEAP study (ALK-Abelló) and the same lancet device. Blood samples 147 
were obtained at clinic attendance and total and sIgE levels to peanut, egg, and other relevant foods 148 
based on clinical history, were measured using ImmunoCAP System FEIA (Phadia AB, Uppsala, 149 
Sweden). 150 
Ethics 151 
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Ethical approval was obtained from the Office for Children Human Research Ethics Committee 152 
(HREC; ref no CDF/07/492), Department of Human Services HREC (ref no 10/07), and Royal 153 
Children’s Hospital HREC (ref no 27047). Parents/guardians of all participants provided written 154 
informed consent.  155 
Definitions 156 
Eczema in the first year of life was defined as a diagnosis of eczema, to identify those infants who 157 
would already be identified through the medical system.  158 
Early moderate/severe eczema was defined as diagnosed eczema starting in the first 6 months of life 159 
and treated with topical steroids (either over-the-counter or prescribed). Severity of eczema is defined 160 
variably with SCORAD or by ill-defined doctor specific grading so for the purposes of this analysis, 161 
we used early onset eczema (before 6 months) and requirement for topical steroid therapy to identify 162 
more severe eczema. This would also offer a consistent approach to identifying these infants in 163 
practice if the international consensus recommendations are to be adopted.  164 
Egg allergy was defined as challenge-proven egg allergy at 1 year of age, in the presence of sIgE to 165 
egg detected either by SPT (wheal size ≥ 2mm above saline control) or serum sIgE levels 166 
(≥0.35kUA/L).  167 
Peanut allergy was defined as challenge proven peanut allergy at 1 year of age. All infants with a 168 
positive peanut challenge had peanut sIgE detected by either SPT or serum sIgE.  169 
The following definitions were used for risk stratification:  170 
High-risk infants were defined as those with either egg allergy or early onset (≤6 months) 171 
moderate/severe eczema – these infants would potentially have been eligible for inclusion in the 172 
LEAP study,1 depending on the age of manifestation of egg allergy and the severity of eczema. A 173 
comparison of definitions of high risk used in LEAP and accompanying editorial and consensus 174 
guidelines is presented in Supplementary Table S1.  175 
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Low-risk infants were defined as those with no egg allergy and no early onset (≤6 months) 176 
moderate/severe eczema. It should be noted that this category of infants includes those with late onset 177 
or mild forms of eczema.  178 
Statistical methods  179 
We calculated the proportion of participants in the HealthNuts cohort who: (1) were classified as 180 
“high risk” and “low risk”; (2) had challenge-proven peanut allergy in each of the high-risk and low-181 
risk groups; and (3) calculated the proportion of all peanut allergy cases that occurred in high-risk and 182 
low-risk infants. Proportions were calculated as percentages with 95% confidence intervals calculated 183 
assuming a binomial sampling distribution.  184 
SPT wheal sizes and peanut sIgE levels were classified for analysis into groups according to a 185 
combination of clinical cut-offs and those used in the LEAP study1 to define the SPT-Positive group 186 
(SPT 1-4mm) and the likely peanut allergy group (SPT>4mm). Thus SPT results were grouped into 187 
0mm (not sensitized); 1-2mm (SPT-positive according to LEAP but not generally considered 188 
sensitized by clinical criteria); 3-4mm (sensitized according to both LEAP and standard clinical cut-189 
offs) and >4mm (likely peanut allergic according to LEAP). sIgE to peanut was grouped into 190 
<0.1kUA/L (below the limit of detection); 0.1-0.34 (detectable but below usual clinical cut-offs for 191 
sensitization); 0.35-17.4 (sensitized) and ≥17.5 (high positive). The proportion of positive challenges 192 
in each SPT or sIgE category was calculated with 95% confidence intervals as above.  193 
To investigate factors associated with age at introduction of peanut into the infant diet, the cohort was 194 
divided into groups according to the risk factors: family history of eczema or food allergy, infant 195 
eczema, and infant history of reaction to egg or milk. Challenge-confirmed egg allergy was not used 196 
in this analysis because SPT and challenges to egg occurred after parents had already made the 197 
decision on when to introduce peanut to their child. Chi-squared p-values were calculated comparing 198 
the distribution of age at peanut introduction in each risk group to the baseline group of “no risk 199 
factors”.  200 
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We modelled the potential proportion of peanut allergy cases in the community that might be 201 
prevented by applying the LEAP intervention findings to the general population using the following 202 
steps:  203 
1. We used a hypothetical population of 1,000 infants to represent the general population  204 
2. We used the actual prevalence of early onset eczema and/or egg allergy in HealthNuts to split 205 
the population into “low-risk” and “high-risk” groups 206 
3. We assumed that the LEAP intervention would only be applied to the high-risk group (as per 207 
the current consensus guidelines8 ). We used HealthNuts data to estimate the prevalence of 208 
peanut allergy in the low-risk group without intervention (i.e. the HealthNuts observed 209 
prevalence of peanut allergy among low-risk infants).  210 
4. We used direct percentages from the LEAP study1 to estimate the proportion of high-risk 211 
infants who would have a SPT>4mm to peanut at 4-11 months of age.  212 
5. We used HealthNuts data to estimate the proportion of infants with a SPT >4mm who would 213 
be peanut allergic (80%) as this data was not available from the LEAP study.  214 
6. We used direct percentages from the LEAP control arm to estimate the prevalence of peanut 215 
allergy without intervention (17%) and direct percentages from the LEAP intervention arm to 216 
estimate the prevalence of peanut allergy with timely peanut introduction between 4-11 217 
months (3%), and thus calculated the proportion of cases that could be prevented.  218 
  219 
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Results 220 
Characteristics of the HealthNuts study cohort  221 
Study participation is shown in Supplementary Figure 1. Relevant characteristics of the HealthNuts 222 
study cohort are described in Table 1. Our previous work has shown that the HealthNuts participants 223 
are generally representative of the infant population of metropolitan Melbourne as compared to the 224 
state-mandated Victorian perinatal database.10 225 
Proportion of peanut allergy cases in the general population occurring in high- and low-risk infants  226 
Table 2 shows peanut allergy prevalence by eczema and egg allergy status. Overall 84% of the 227 
population were classified as “low risk” (no early moderate/severe eczema or egg allergy), with 0.8% 228 
of these infants having challenge-confirmed peanut allergy (Table 2). This represents 23% of all 229 
peanut allergy cases in the population, who would be missed by targeting only high-risk infants.  The 230 
remaining 16% of the population were classified as “high risk” by this definition, and 14% of these 231 
infants were peanut allergic. This represents 77% of all peanut allergy cases in the population. The 232 
highest risk of peanut allergy was in infants with both early moderate/severe eczema and egg allergy 233 
(who represented 3.5% of the general population), with 35% of these infants having peanut allergy. 234 
Peanut allergy was more common in infants with egg allergy than those without egg allergy, 235 
irrespective of their eczema status.  236 
Characterizing SPT and sIgE levels to peanut at the population level  237 
The distribution of SPT wheal sizes and sIgE levels in the cohort are shown in Figure 1. Compared to 238 
low-risk infants, high-risk infants were more likely to have a detectable wheal on peanut SPT: 29% 239 
(95%CI 25.8, 32.4) vs 4% (95%CI 3.4, 4.7), p<0.001. Among high-risk infants with a 0mm SPT to 240 
peanut, 34% had detectable levels of sIgE to peanut. No infants with a negative (0mm) SPT or peanut 241 
sIgE below the limits of detection had a positive peanut OFC in either the high or low-risk groups; 242 
however some positive peanut challenges occurred in infants with a SPT wheal size or sIgE level 243 
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below the traditional cut-offs for sensitization (3mm for SPT and 0.35kUA/L for sIgE) (Figure 1c and 244 
Figure 1d).  245 
Using the SPT cut-off values defined in the LEAP study as “likely peanut allergy” (SPT wheal size 246 
>4mm), 70.3% (95% CI 54.8, 85.7) of low-risk infants and 80.2% (95% CI 73.0, 87.4) of high-risk 247 
infants were allergic on OFC (Table 3).   248 
Prevalence and types of adverse reactions to peanut in the first year of life among infants who 249 
introduced peanut at home prior to study participation 250 
Overall 30% of infants were introduced to peanut by their parents before 12 months of age 251 
(predominantly in the form of peanut butter, data not shown). Infants with eczema or a personal 252 
history of reactions to other foods (egg or milk) were less likely to be given peanut before 12 months 253 
of age, while a family history of food allergy or eczema had little impact on the age of peanut 254 
introduction in the absence of any clinical signs of allergy in the infant (Table 4). Only 13% of infants 255 
with both early eczema and a history of reaction to milk or egg were introduced to peanut by 12 256 
months of age.  257 
Of those infants introduced to peanut by their parents by age 12 months, 3% reported a possible 258 
reaction, with the majority of these (82%) occurring within 1 hour of ingestion, consistent with IgE-259 
mediated reactions. Reactions occurred more commonly in high-risk infants (10.6% vs 1.4%, 260 
p<0.001). Table 5 shows the types of reactions. Only one infant had a history consistent with possible 261 
anaphylaxis (wheeze/difficulty breathing) with peanut being the reported food causing this reaction 262 
(when given at age 12 months), however this child was later shown to tolerate peanut on OFC at age 263 
14 months.  264 
Prevalence and types of adverse reactions to peanut during hospital-based oral food challenge  265 
The most common reaction to peanut OFC, irrespective of SPT wheal size or risk profile, was 266 
urticaria (Table 6). Anaphylaxis occurred in 6 challenges (4% of positive challenges), with cases of 267 
anaphylaxis seen in both high and low-risk groups.  268 
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Applying the proportion of peanut allergy cases that may be preventable by applying LEAP 269 
intervention to the general population  270 
We used the best available data from either HealthNuts or LEAP to model the proportion of peanut 271 
allergy cases that might be preventable if the LEAP intervention findings were applied to a 272 
hypothetical population of 1,000 infants (Figure 2), with the following assumptions:  273 
1. 84% of the population are low-risk and 16% high-risk (HealthNuts data) 274 
• Of the low-risk infants, 0.8% are peanut allergic without intervention (HealthNuts data) 275 
• Of the high-risk infants, 89% would have a SPT≤4mm and 11% would have a SPT>4mm 276 
if screened at 4-11 months of age (LEAP data). Note that this is lower than the observed 277 
proportion of high-risk infants with a SPT>4mm in HealthNuts (14.6%), probably 278 
because infants in HealthNuts were older (12 months) at time of skin prick test.  279 
2. 17% of high-risk infants with a 0-4mm wheal would be allergic without intervention (LEAP data 280 
– peanut avoidance arm). Note that this is higher than the observed proportion of high-risk infants 281 
with a 0-4mm wheal who are peanut allergic in HealthNuts, possibly because of (1) older age in 282 
HealthNuts, and/or (2) earlier introduction of peanut in the HealthNuts cohort compared with the 283 
LEAP control arm.  284 
3. 3% of high-risk infants with a 0-4mm wheal would be allergic with intervention (LEAP data – 285 
early peanut introduction arm).  286 
These assumptions were used to calculate the number of cases of peanut allergy in this constructed 287 
population that would be expected with and without intervention, and therefore the proportion of 288 
peanut allergy cases that could be prevented through the early introduction of peanut. Note that the 289 
proportion of cases that would be expected in low- and high-risk infants in this hypothetical 290 
population does not match that observed in HealthNuts, because of the differences between LEAP and 291 
HealthNuts described in assumptions 1-3 above.  292 
If the LEAP intervention findings were applied to all infants with early onset eczema and/or egg 293 
allergy, 44% of all peanut allergy cases in the community might be prevented (Figure 2; 20/45 = 294 
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44%). If the same magnitude of risk reduction (80%; 6 of 7 cases prevented) could be achieved in 295 
low-risk infants, a total of 58% of peanut allergy cases in the community might be prevented (26/45 = 296 
58%). This would increase to 64% of cases if timely peanut introduction could also be implemented 297 
and was protective in the 20% of infants with a SPT wheal >4mm who are negative on baseline 298 
challenge (29/45=64%). If timely peanut introduction was half as successful at preventing peanut 299 
allergy in low-risk infants compared to high-risk infants (e.g. 40% of cases prevented instead of 80%), 300 
and not implemented in the SPT>4mm group, a total of 51% of peanut allergy cases might be 301 
prevented (23/45 = 51%).  302 
303 
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Discussion 304 
Our study extends the findings of the LEAP trial1 to a population-based cohort. We show that using 305 
the strict criteria applied in LEAP to select high-risk infants to target early introduction of peanut 306 
would miss a sizeable number of peanut allergy cases in the general community. Even using very 307 
inclusive criteria to define “high risk” (all infants with early onset eczema and/or egg allergy) to target 308 
screening, 23% (95% CI 16.6, 31.3) of peanut allergy cases in the population would still be missed. 309 
Furthermore, 29% (95% CI 25.8, 32.4) of these high-risk infants could have a positive SPT. If the 310 
current international consensus guidelines were followed, these infants would require clinical follow 311 
up to assist with assessment for timely introduction of dietary peanut, which is a large proportion of 312 
the general infant population.  313 
Using a combination of data from LEAP and HealthNuts to model the potential impact of 314 
implementing the LEAP intervention in the wider population, we show that this might only prevent up 315 
to 44% of peanut allergy cases if the intervention is restricted to high-risk infants. New strategies in 316 
addition to earlier introduction of peanut need to be investigated in future studies to prevent peanut 317 
allergy in those infants whose peanut allergy develops too early to benefit from the early introduction 318 
intervention. Further research to determine whether earlier introduction of peanut is also beneficial in 319 
low-risk infants may also be warranted. The recently published EAT trial compared peanut 320 
introduction (along with other allergenic foods) from 3 months (although actual reported median age 321 
at introduction was around 5 months) with introduction after 6 months of age in population-recruited 322 
infants (with and without eczema). The primary analysis (intention to treat) showed no significant 323 
difference in peanut allergy in the two groups, although there was a lower prevalence of peanut 324 
allergy in the early introduction group in a secondary per protocol analysis. High- and low-risk infants 325 
were not analysed separately.9  326 
We add to the findings of the LEAP trial by showing that around 80% (95% CI 73.0, 87.4) of high-327 
risk infants with a SPT wheal size >4mm, excluded from participation in LEAP, had challenge 328 
confirmed peanut allergy. Conversely, 20% of infants with a SPT wheal size >4mm could tolerate 329 
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peanut. Thus if screening were implemented and this cut off used, an inappropriate recommendation 330 
to avoid peanut might be made for these high-risk infants. Identifying peanut tolerant infants through 331 
peanut OFC so that they can be included in the earlier introduction of peanut group could improve the 332 
proportion of peanut allergy cases prevented, although no data are currently available on the potential 333 
beneficial effect of early peanut introduction in preventing peanut allergy later in life in infants with 334 
such size SPT. If a cut off is to be used to identify infants who are highly likely to be peanut allergic, 335 
and thus reduce the need for food challenges, a more appropriate level might be wheal sizes of 8mm 336 
or greater, which has previously been shown to have a 95% positive predictive value for peanut 337 
allergy in infants.13 338 
Our results obtained from a general population cohort also confirm other findings from the high-risk 339 
LEAP cohort. We showed that even high-risk infants with SPT wheal sizes of 1-4mm are likely to 340 
tolerate peanut if introduced early in life. We also found that positive challenges occurred in some 341 
infants with a peanut SPT wheal size of 1-2mm, below the traditional cut-off of 3mm, and in infants 342 
with a peanut sIgE level between 0.1-0.34. A further interesting confirmation of the LEAP study was 343 
the finding that 34% of high-risk infants with a 0mm SPT to peanut had detectable levels of peanut 344 
sIgE – in the LEAP cohort 28% of SPT negative infants had detectable peanut sIgE.1  345 
The strengths of this study include the careful peanut allergy phenotyping of a large cohort of infants 346 
through hospital supervised OFCs, and the fact that the same SPT device, commercially available 347 
allergen extract and OFC methodology as LEAP were used. In this context it is striking that predictive 348 
values for peanut allergy in the <4mm SPT group were consistent across both studies, despite one 349 
study being only high-risk infants and the other population based, with two independent study teams 350 
performing the testing. If SPT is to be considered for screening it is therefore likely to be a robust 351 
methodology.  352 
The findings of this study are likely to be generalizable to the wider Victorian population due to the 353 
population-based sampling frame and high participation rate. We have evidence that study 354 
participants are generally representative of all births in Victoria from data collected routinely in the 355 
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perinatal database.10 In addition, we have previously shown that weighting prevalence estimates, 356 
using data on the prevalence of risk factors for peanut allergy in all eligible infants whose parents 357 
declined study participation, only marginally altered the prevalence estimate for peanut allergy from 358 
3.0% to 2.9%.2 359 
Despite the large sample size of this study, peanut allergy is a relatively uncommon outcome in the 360 
general population. As a result, some SPT and sIgE groups only include a small number of infants, 361 
resulting in wide confidence intervals. Our findings need to be interpreted in conjunction with the 362 
magnitude of uncertainty around each of the reported estimates.  363 
Limitations include that although study participants were peanut challenged within 4-8 weeks of their 364 
screening SPT at their 12 month immunization visit, our results pertain to children 12-18 months 365 
which is an older age group than that recruited into LEAP. However, despite the difference in age 366 
range, key results are remarkably similar across the two cohorts. Additionally different definitions of 367 
eczema were used across the cohorts, with infants included in LEAP likely representing more severe 368 
eczema cases. Both definitions have limitations since both incorporated the somewhat subjective 369 
criteria of parental report of eczema severity and topical steroid use. Defining eczema severity 370 
remains problematic so we chose a definition that would identify infants who would be seen through 371 
the medical system, with early onset and requirement for topical steroid therapy used to identify more 372 
severe eczema. This would also offer a consistent approach to identifying these infants in practice if 373 
the international consensus recommendations are to be adopted. Restricting the definition to capture 374 
only more severe cases of eczema would increase the number of peanut allergy cases missed.  375 
What are the implications of our findings for clinical practice and the potential to implement 376 
screening guidelines? As reported in other population-based studies of infants, eczema and egg 377 
allergy are common in infancy,2,14,15 although egg allergy appears somewhat more common in 378 
Australia than in Europe16; thus even if only high-risk infants were targeted a relatively large 379 
proportion of the population would require screening at least in some countries. Consistent with 380 
previous studies,17 we show that both SPT and sIgE to peanut have a strong negative predictive value. 381 
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Screening could therefore potentially include some testing in the community setting using peanut sIgE 382 
blood tests, perhaps in combination with Ara h2 as a second step,18 making screening more feasible 383 
and reducing the number needing SPT and/or OFC. Furthermore egg allergy was a stronger predictor 384 
of peanut allergy than eczema alone; however since less than 25% of infants had introduced egg by 6 385 
months of age, this is unlikely to be a helpful early marker for targeting early onset allergic disease for 386 
screening as recommended by consensus guidelines.8 Further studies will need to be done to 387 
investigate the potential implications of implementing screening in other countries including the US, 388 
which may have different rates of eczema and peanut allergy.  389 
An alternative paradigm to screening high-risk infants would be to recommend timely introduction of 390 
peanut for all infants irrespective of allergy risk, as per the current Australian guidelines.19 Our 391 
findings provide some reassurance that reactions at home when peanut was introduced as part of a 392 
weaning diet before 12 months were uncommon overall, with no (clear) cases of anaphylaxis 393 
reported. However, there was evidence of self-selection based on risk, whereby infants with eczema 394 
or egg allergy were less likely to introduce peanut before 1 year of age – and this group were more 395 
likely to react on introduction – thus it is difficult to predict whether severe reactions would have 396 
occurred in peanut was introduced to all high-risk infants at home in an uncontrolled manner. The fact 397 
that peanut-allergic infants usually had mild reactions during supervised challenges provides some 398 
reassurance. While LEAP did not look at whether early introduction of peanut in low-risk group 399 
might lead to reduced risk of peanut allergy, this may be a reasonable recommendation for the 400 
population, since data from HealthNuts suggest likelihood of reaction is low and reactions were mild-401 
moderate. The publication of the LEAP trial, resulting media coverage, and release of international 402 
consensus guidelines stating that delay in peanut introduction might be harmful, is likely to encourage 403 
more parents to introduce peanut earlier in infancy, and the HealthNuts study provides baseline data 404 
against which to measure changes in timing of peanut introduction and the resulting impact on peanut 405 
allergy prevalence.   406 
We provide data that the majority of reactions on peanut introduction in young infants are mild, 407 
irrespective of whether peanut it is introduced at home or in the hospital, and irrespective of SPT 408 
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wheal size or clinical risk factors. Caution is needed in interpretation of these results since despite the 409 
large population recruited the number of peanut-allergic infants was only 150 cases – more severe 410 
reactions might still be observed in rare cases. However, in conjunction with findings from the LEAP 411 
study, our findings provide reassurance that introducing peanut in infancy is unlikely to lead to severe 412 
reactions. In fact, since infants in HealthNuts were already 1 year of age and had predominantly 413 
avoided peanut in infancy, thus increasing their likelihood of being peanut allergic, we would expect 414 
to see even fewer reactions if peanut was introduction earlier in the first year of life as in LEAP.  415 
In conclusion, our results show that large numbers of infants would be affected if screening prior to 416 
introduction of peanut was implemented; thus careful consideration of whether and how to target 417 
and/or screen infants is required before public health recommendations can be made. Despite the 418 
potential to substantially reduce the population prevalence of peanut allergy through timely 419 
introduction of peanut high-risk infants, around 20% of peanut allergy cases in the population occur in 420 
low-risk infants and an additional 20% of cases occur in infants ineligible for participation due to a 421 
SPT wheal size >4mm at recruitment. Additional prevention strategies will be required for these 422 
infants. Further population-based intervention trials are required to determine whether timely 423 
introduction of peanut is also protective for low-risk infants, and to inform cost-effective analysis of 424 
the intervention at the population level as well as cost-effectiveness of various screening strategies.  425 
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Tables and Figure Legends 
Table 1: Characteristics of the HealthNuts cohort  
*Negative SPT to all tested foods at recruitment 
† Percentages may not add up to 100% due to missing data  
 
 
 
Characteristic 
Negative (0mm) SPT to peanut at 12 months    
 
Detectable wheal on 
peanut SPT (≥1mm) 
and attended clinic 
N=417 
Attended HealthNuts 
clinic as controls* 
N=197 
Did not attend 
HealthNuts clinic 
N=3857 
Attended 
HealthNuts clinic 
due to sensitization 
to other food/s 
N=428 
Age (months, SD) at 
recruitment 
12.6 (0.7) 12.7 (0.7) 12.6 (0.7) 12.7 (0.7) 
Age (months, SD) at clinic 
attendance 
14.6 (1.2) - 14.4 (1.3) 14.3 (1.2) 
Male sex 48% 50% 50% 60% 
Eczema†     
None 68% 77% 55% 36% 
Eczema starting ≤ 6mth 
treated with topical steroids 
11% 6% 20% 35% 
Eczema starting ≤ 6mth no 
topical steroids 
10% 6% 9% 12% 
Eczema starting >6mths of 
age 
7% 4% 7% 7% 
Age at egg introduction†     
≤ 6 months 22% 25% 18% 23% 
7-12 months 70% 68% 71% 62% 
Not yet given  5% 3% 5% 10% 
Egg allergic‡  - - 51% 47% 
Peanut sIgE measured 77% - 83% 86% 
Peanut OFC completed 68% - - 90% 
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‡ Defined as challenge-proven egg allergy at 1 year of age, in the presence of sIgE to egg detected either by skin 
prick test (wheal size ≥ 2mm above saline control) or serum sIgE levels (≥0.35kUA/L).
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Table 2:  Proportion of peanut allergy cases in the HealthNuts population-based sample occurring in high- and low-risk infants  
Clinical profile Eczema status  Egg allergy  N Proportion of the 
population with this 
risk profile 
% (95% CI) 
Proportion with 
peanut allergy at 
age 1 year 
% (95% CI) 
Proportion of peanut 
allergy cases captured 
(total n=137‡) 
% (95% CI) 
Low risk None No 3338 72.2 (70.9, 73.5) 0.6  (0.3, 0.8) 13.9 (8.6, 20.8) 
 Later onset or mild eczema† No 535 11.6 (10.7, 12.5) 2.4 (1.1, 3.7) 9.5 (5.1, 15.7) 
 Low-risk group: total 3873 83.8 (82.7, 84.8) 0.8 (0.5, 1.1) 23.4 (16.6, 31.3) 
High risk None Yes 167  3.6 (3.1, 4.2) 10.8 (6.0, 15.5) 13.1 (8.0, 20.0) 
 Later onset or mild eczema† Yes 82 1.8 (1.4, 2.2) 20.7 (11.8, 29.7) 12.4 (7.4, 19.1) 
 Early moderate/severe eczema*  No 338 7.3 (6.6, 8.1) 3.8 (1.7, 5.9) 9.5 (5.1, 15.7) 
 Early moderate/severe eczema*  Yes 164 3.5 (3.0, 4.1) 34.8 (27.4, 42.1) 41.6 (33.3, 50.3) 
 High-risk group: total 751 16.2 (15.2, 17.3) 13.9 (11.5, 16.5) 76.7 (68.7, 83.4) 
* Diagnosed eczema starting ≤ 6 mths of age & treated with topical steroids 
† Diagnosed eczema starting > 6 mths of age & treated with topical steroids or eczema (at any age) without topical steroid treatment 
‡ Of the cases that could be classified into high- or low-risk groups (complete data on eczema and egg allergy status)
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Table 3: Proportion of positive peanut challenges by skin prick test wheal and specific IgE cut-offs in 
high- and low-risk populations 
Risk group   SPT wheal size/ 
sIgE level 
(kuA/L) 
Number of 
peanut OFC 
performed 
% of peanut OFC 
that were positive 
(95% CI) 
Low risk (No early eczema and/or 
egg allergy) 
SPT: 0mm* 154 0%  
(0, 2.4)† 
SPT: 1-2mm 23 0% 
(0, 14.8)† 
SPT: 3-4mm 16 12.5% 
(0, 30.7) 
SPT: >4mm 37 70.3% 
(54.8, 85.7) 
High risk (early eczema [≤6 mths, 
requiring topical steroids] and/or 
egg allergy) 
SPT: 0mm* 72 0% 
(0, 5.0)† 
SPT: 1-2mm 44 11.4%  
(3.8, 24.6) 
SPT: 3-4mm 51 5.9%  
(0, 12.6) 
SPT: >4mm 121 80.2%  
 (73.0, 87.4) 
Low risk (No early eczema and/or 
egg allergy) 
sIgE: <0.1 ** 131 0% 
(0, 2.8)† 
 sIgE: 0.1-0.34 24 20.8% 
(3.3, 38.4) 
 sIgE: 0.35-17.4 51 43.1% 
(29.1, 57.2) 
 sIgE: ≥17.5 4 75.0%  
(19.4, 99.4) 
High risk (early eczema [≤6 mths, 
requiring topical steroids] and/or 
egg allergy) 
sIgE: <0.1** 31 0% 
(0, 11.2)† 
 sIgE: 0.1-0.34 28 21.4% 
(5.2, 37.6) 
 sIgE: 0.35-17.4 133 43.6%  
(35.1, 52.1) 
 sIgE: ≥17.5 27 81.5% 
(65.8, 97.1) 
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*Selected for challenge based on previous detectable SPT wheal in the community but subsequently 
negative on repeat SPT in clinic (n=81; 54 of these were <3mm initially) or as negative control group 
with two negative skin prick tests (n=140)  
**Below detection 
†One sided, 97.5% confidence interval 
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 Table 4: Relationship between family history of allergy and signs of allergy in the infant and age at introduction of peanut into the infant diet 
Family history of allergy and allergic 
symptoms in the infants prior to 12 months 
of age 
 Age at introduction of peanut  
N 4-6 mths 7-8 mths 9-10mths 11-12 mths Not yet given P* 
No risk factors  2215 3.6% 5.4% 8.6% 12.2% 69.9%  
Family history of eczema or food allergy 
only (parents or siblings) 
1677 2.6% 4.9% 8.4% 12.3% 71.8% 0.32 
Early eczema only (eczema ≤6mths treated 
with topical steroids) 
418 1.8% 4.4% 6.9% 8.2% 78.2% 0.014 
Early eczema and infant history of reaction 
to milk or egg (parent-reported) 
181 0.6% 1.8% 3.6% 6.7% 87.3% <0.001 
*Chi2 p value comparing the distribution of age at peanut introduction in each risk group to the baseline group of “no risk factors”  
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Table 5: Prevalence and types of community based adverse reactions to peanut in the first year of life in infants who introduced peanut at home prior to skin 
prick test screening at 12 months of age   
   Reported reaction within 1 hour (possibly IgE-mediated)† 
   Skin only 
(hives, rash, swelling 
of lips, eyes or face) 
Gut only 
(vomiting, diarrhoea) 
Skin & gut Wheeze/ difficulty 
breathing 
 Number 
introduced to 
peanut 
% reporting a 
reaction 
N Challenge 
confirmed 
peanut allergy 
N Challenge 
confirmed 
peanut allergy 
N Challenge 
confirmed 
peanut allergy 
N Challenge 
confirmed 
peanut allergy 
Low-risk group (no early 
eczema or egg allergy) 
1135  1.2% 14 31% (4/13) 0 - 0 - 0 - 
High-risk group (early eczema 
or egg allergy) 
185 9.7% 15 67% (10/15) 0 - 2 100% (2/2) 1* 0 
 
* Reaction occurred on first reported introduction of peanut butter at 12 months of age. Vomiting also reported. Note – child had a negative SPT at age 12 
months (1mm) and sIgE to peanut and a negative OFC to peanut at age 14 months in clinic, and tolerated peanut (1tsp per day) for a week at home post 
challenge with no reaction, so peanut allergy unlikely or outgrown. Child had positive SPT and sIgE to hazelnut at age 14 months. 
† An additional 6 infants had a reported reaction occurring 1-4 hours after ingestion, with 5 involving skin only (1 positive on challenge) and 1 skin and gut 
(negative challenge). An additional 3 infants had a reported reaction > 4 hours after ingestion, all involving skin only (2 positive on challenge).   
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Table 6: Reactions to peanut on oral food challenge at 12 months of age  
Skin prick test 
wheal size  
Number of 
peanut OFC 
Number 
positive 
OFC 
Hives‡ 
 (% of positive 
challenges) 
Angioedema‡ 
 (% of positive 
challenges)  
Vomiting‡ 
(% of positive 
challenges) 
Skin & gut‡ 
(% of positive 
challenges) 
Anaphylaxis‡* 
(% of positive 
challenges)  
0 mm 221 0 - - - - - 
Low risk group (no early eczema or egg allergy)     
1-4 mm 43 2 (5%)† 1 (50%) 0 1 (50%) 0 0 
5-7 mm  20 11 (55%) 10 (91%) 0 0 0 1 (9%) 
>8mm  23 20 (87%) 17 (85%) 3 (15%) 1 (5%) 1 (5%) 0 
High risk group (early eczema or egg allergy)      
1-4 mm 94 8 (9%)† 6 (75%) 0 0 0 0 
5-7 mm  50 30 (60%) 24 (80%) 2 (7%) 2 (7%) 2 (7%) 2 (7%) 
>8mm  69 65 (94%) 59 (91%) 13 (30%) 10 (15%) 10 (15%) 3 (5%) 
* All infants developed respiratory symptoms (wheeze) and were treated with adrenaline (single dose in each cases) and Ventolin, +/- Zyrtec.  
† 3 children in this category had a negative day 1 hospital based challenge but reacted on continued consumption of peanut at home, all with hives 
+ eczema flare +/- angioedema – these reactions are not presented in the table but the infants are included in the “number positive OFC” column.  
‡ Note that categories are not mutually exclusive, e.g. all of the children with skin & gut reaction also appear in both the skin (hives or angioedema) 
and gut (vomiting) columns 
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Figure Legends 
Figure 1: Characterizing peanut SPT wheal size and specific IgE levels in a population based sample 
of infants, stratified by high risk (early eczema and/or egg allergy) or low risk (no early eczema 
and/or egg allergy) groups. (a) Proportion of infants sensitized to peanut on community-based skin 
prick test. (b) Relationship between skin prick and sIgE results to peanut among infants attending 
food challenge clinic. (c) Relationship between peanut skin prick results and challenge outcome 
among infants attending food challenge clinic.* (d) Relationship between peanut sIgE results and 
challenge outcome among infants attending food challenge clinic. 
*Infants with a 0mm SPT wheal for peanut included infants selected for challenge based on previous 
detectable SPT wheal in the community (n=81; 54 of these were <3mm) or as part of a negative 
control group (0mm skin prick test to peanut in both community and clinic, n=140). Numbers in each 
analysis differ due to the study design: skin prick testing to peanut was performed as a screening step 
for all infants, but only infants attending challenge clinic had blood taken for sIgE measurement (83% 
of those attending clinic agreed to give a blood sample).   
Figure 2: Cases of peanut allergy that may be theoretically preventable by applying the LEAP 
intervention findings to a general infant population†  
† We used a hypothetical population of 1,000 infants to represent the general population. At each step, 
we used the best available observed data from either HealthNuts (blue; this study) or LEAP (black) 
[1] to calculate the proportion of this hypothetical population that would fall into each group, and the 
prevalence of peanut allergy in each group. Precedence was given to data from the LEAP study where 
available.  
* The proportion of peanut allergy cases predicted to develop in the 0-4mm SPT group without 
intervention is the observed proportion of children with peanut allergy in the control arm of the LEAP 
study. This may be higher than actually observed in a “real world” setting since some of these 
children might have been introduced to peanut earlier if they were not participating in this randomized 
trial and thus instructed to avoid peanut until age 5 years. The proportion of peanut allergy cases 
predicted to develop in the 0-4mm SPT group with intervention is the observed proportion of children 
with peanut allergy in the intervention arm of LEAP in the intention to treat analysis.  
‡ We used figures from the LEAP study [1] to estimate the proportion of high risk infants who would 
have a SPT>4mm to peanut at 4-11 months of age. This figure (10.6%) is somewhat lower than the 
proportion of high risk infants in HealthNuts with a SPT>4mm (14.6%), possibly because infants in 
HealthNuts were older at the time of SPT (12 months of age) 
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Supplementary Figure E1:   
 
Recruitment at immunisation sessions (age 12 months) 
Non-responders 
Consent to participate 
N=5,276 (74% participation) 
Questionnaire & skin prick test to  
peanut, egg, sesame, shellfish/cow’s milk 
Short questionnaire: 
•  Allergies in the child 
•  Consumption of peanut 
•  Allergies in family members 
Negative SPT to all tested foods 
(wheal size 0 mm) 
SPT wheal size ≥ 1mm greater  
than negative control invited  
to HealthNuts allergy clinic 
N=1001 (19%) 
Subset invited to HealthNuts  
clinic as controls
†
 
N=197 attended 
Attended clinic (age 14-16 mths):  
N=845 (84%) 
N=329 SPT ≥ 1mm to peanut 
N=509 SPT 0mm to peanut
‡
 
 
†
Non-sensitised controls for lab 
studies. Food challenged to either 
egg or peanut, and blood collected 
for sIgE measurement, 
immunology etc.  
‡ 
86 of these infants had a peanut SPT 
≥1mm at recruitment, thus had peanut 
OFC despite negative SPT at clinic. The 
remainder attended clinic due to 
sensitisation to other foods (not peanut) 
and did not undergo peanut challenge.  
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Online Repository Material  
Table E1: Comparison of definitions of high risk for development of peanut allergy used in the LEAP 
randomized controlled trial and subsequent editorials and consensus guidelines  
 LEAP randomized controlled 
trial  
Editorial accompanying the 
LEAP study  
Consensus guidelines 
Age range 
targeted 
4-11 months 4-8 months 4-11 months 
Eczema definition Severe eczema (89% of 
participants):   
Requires application of topical 
creams, ointments, or both 
containing corticosteroids or 
calcineurin inhibitors and that, 
if the participant is <6 months 
of age, lasted for at least 12 of 
30 days on 2 occasions or, if 
the participant is >6 months of 
age, lasted for at least 12 of 30 
days on 2 occasions in the last 
6 months 
OR 
Is currently or was previously 
graded ≥40 by using the 
modified SCORAD evaluation 
“Any infant between 4 
months and 8 months of 
age believed to be at risk 
for peanut allergy”  
Severe eczema as per LEAP 
definition. If occuring in first 
4 to 6 months of life – 
“might benefit from 
evaluation by an allergist”  
Egg allergy 
definition 
Egg allergy (64% of 
participants): 
SPT wheal ≥ 6mm to raw 
hen’s egg white and no history 
of previous egg tolerance 
OR 
SPT wheal ≥ 3mm to 
pasteurized hen’s egg white 
and allergic symptoms related 
to exposure to hen’s egg 
As above  Egg allergy as per LEAP 
definition. If occurring in  
first 4 to 6 months of life - 
“might benefit from 
evaluation by an allergist” 
Peanut SPT cut-
offs and 
recommendations  
0-4mm: Included  
>4mm: Excluded 
0mm: Start peanut 
containing diet 
1-4mm: Peanut challenge – 
if negative, start peanut 
containing diet 
>4mm: No 
recommendations 
Clinician can perform an 
observed peanut challenge 
for those with evidence of a 
positive peanut skin test 
response to determine 
whether they are clinically 
reactive before initiating at-
home peanut introduction 
